Asymchem Laboratories (Tianjin) (002821) Q3 2026 earnings summary

Executive summary

• Q3 revenue was RMB 1.788bn, up 24.04% YoY; net profit attributable to shareholders was RMB 331.7m, up 81.49% YoY.

• 9M revenue reached RMB 5.395bn, up 16.52% reported and 20.00% at constant exchange rates; adjusted net profit rose 21.81% YoY to RMB 1.074bn.

• New orders maintained double-digit YoY growth; management expects FY2026 revenue growth of 19%–22%, with Q4 deliveries substantially above Q3.

Financial highlights

• 9M net profit attributable to shareholders was RMB 852.2m, up 6.49% YoY; adjusted net profit was RMB 1.074bn, up 21.81%.

• Q3 net profit excluding non-recurring gains was RMB 203.5m, up 25.70% YoY; 9M net profit excluding non-recurring gains was RMB 728.3m, up 0.04%.

• 9M non-recurring gains totaled RMB 123.9m after tax, including RMB 104.4m in financial-asset fair-value and disposal gains before tax.

• 9M weighted average ROE was 4.75%, up 0.12 percentage points YoY; total assets at period-end were RMB 21.634bn, up 6.69% from year-end 2025.

Outlook and guidance

• FY2026 revenue growth is expected at 19%–22%; late-stage clinical and commercial projects typically deliver in greater volumes in H2.

• Backlog scheduled for delivery indicates Q4 delivery volume will increase substantially versus Q3.